News | February 03, 2009

Cerenis In-Licenses Technology for New Treatment of Aortic Valve Stenosis

February 3, 2009 - Cerenis Therapeutics SA, a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy.

The intellectual property is based on breakthrough research from a team led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre, Canada.

AVS is characterized by a narrowing of the aortic valve, which can obstruct the flow of oxygenated blood from the heart to the rest of the body. As the heart works harder to compensate for the obstruction, the heart muscle thickens and can cause a potentially dangerous imbalance in blood pressure between the heart and body.

In Dr. Tardif's placebo-controlled study in rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness was significantly decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group as well as reduced aortic valve calcification. Results of the study were published in April 2008 in the British Journal of Pharmacology.

For more information: www.cerenis.com.

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init